Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption

Donn J. Colby; Michal Sarnecki; Dan H. Barouch; Somporn Tipsuk; Daniel J. Stieh; Eugène Kroon; Alexandra Schuetz; Jintana Intasan; Carlo Sacdalan; Suteeraporn Pinyakorn; Pornsuk Grandin; Hongshuo Song; Sodsai Tovanabutra; Zhanna Shubin; Dohoon Kim; Dominic Paquin-Proulx; Michael A. Eller; Rasmi Thomas; Mark de Souza; Lindsay Wieczorek; Victoria R. Polonis; Amélie Pagliuzza; Nicolas Chomont; Lauren Peter; Joseph P. Nkolola; Johan Vingerhoets; Carla Truyers; Maria G. Pau; Hanneke Schuitemaker; Nittaya Phanuphak; Nelson Michael; Merlin L. Robb; Frank L. Tomaka; Jintanat Ananworanich

doi:10.1038/s41591-020-0774-y

Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption

Donn J. Colby, Michal Sarnecki, Dan H. Barouch, Somporn Tipsuk, Daniel J. Stieh, Eugène Kroon, Alexandra Schuetz, Jintana Intasan, Carlo Sacdalan, Suteeraporn Pinyakorn, Pornsuk Grandin, Hongshuo Song, Sodsai Tovanabutra, Zhanna Shubin, Dohoon Kim, Dominic Paquin-Proulx, Michael A. Eller, Rasmi Thomas, Mark de Souza, Lindsay WieczorekVictoria R. Polonis, Amélie Pagliuzza, Nicolas Chomont, Lauren Peter, Joseph P. Nkolola, Johan Vingerhoets, Carla Truyers, Maria G. Pau, Hanneke Schuitemaker, Nittaya Phanuphak, Nelson Michael, Merlin L. Robb^*, Frank L. Tomaka, Jintanat Ananworanich

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).

Original language	English
Pages (from-to)	498-501
Number of pages	4
Journal	Nature Medicine
Volume	26
Issue number	4
DOIs	https://doi.org/10.1038/s41591-020-0774-y
State	Published - 1 Apr 2020
Externally published	Yes

Access to Document

10.1038/s41591-020-0774-y

Cite this

Colby, D. J., Sarnecki, M., Barouch, D. H., Tipsuk, S., Stieh, D. J., Kroon, E., Schuetz, A., Intasan, J., Sacdalan, C., Pinyakorn, S., Grandin, P., Song, H., Tovanabutra, S., Shubin, Z., Kim, D., Paquin-Proulx, D., Eller, M. A., Thomas, R., de Souza, M., ... Ananworanich, J. (2020). Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nature Medicine, 26(4), 498-501. https://doi.org/10.1038/s41591-020-0774-y

@article{9310f29df5834c8c845a378c7e3378cf,

title = "Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption",

abstract = "We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).",

author = "Colby, {Donn J.} and Michal Sarnecki and Barouch, {Dan H.} and Somporn Tipsuk and Stieh, {Daniel J.} and Eug{\`e}ne Kroon and Alexandra Schuetz and Jintana Intasan and Carlo Sacdalan and Suteeraporn Pinyakorn and Pornsuk Grandin and Hongshuo Song and Sodsai Tovanabutra and Zhanna Shubin and Dohoon Kim and Dominic Paquin-Proulx and Eller, {Michael A.} and Rasmi Thomas and {de Souza}, Mark and Lindsay Wieczorek and Polonis, {Victoria R.} and Am{\'e}lie Pagliuzza and Nicolas Chomont and Lauren Peter and Nkolola, {Joseph P.} and Johan Vingerhoets and Carla Truyers and Pau, {Maria G.} and Hanneke Schuitemaker and Nittaya Phanuphak and Nelson Michael and Robb, {Merlin L.} and Tomaka, {Frank L.} and Jintanat Ananworanich",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to Springer Nature America, Inc.",

year = "2020",

month = apr,

day = "1",

doi = "10.1038/s41591-020-0774-y",

language = "English",

volume = "26",

pages = "498--501",

journal = "Nature Medicine",

issn = "1078-8956",

number = "4",

}

Colby, DJ, Sarnecki, M, Barouch, DH, Tipsuk, S, Stieh, DJ, Kroon, E, Schuetz, A, Intasan, J, Sacdalan, C, Pinyakorn, S, Grandin, P, Song, H, Tovanabutra, S, Shubin, Z, Kim, D, Paquin-Proulx, D, Eller, MA, Thomas, R, de Souza, M, Wieczorek, L, Polonis, VR, Pagliuzza, A, Chomont, N, Peter, L, Nkolola, JP, Vingerhoets, J, Truyers, C, Pau, MG, Schuitemaker, H, Phanuphak, N, Michael, N, Robb, ML, Tomaka, FL & Ananworanich, J 2020, 'Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption', Nature Medicine, vol. 26, no. 4, pp. 498-501. https://doi.org/10.1038/s41591-020-0774-y

TY - JOUR

T1 - Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption

AU - Colby, Donn J.

AU - Sarnecki, Michal

AU - Barouch, Dan H.

AU - Tipsuk, Somporn

AU - Stieh, Daniel J.

AU - Kroon, Eugène

AU - Schuetz, Alexandra

AU - Intasan, Jintana

AU - Sacdalan, Carlo

AU - Pinyakorn, Suteeraporn

AU - Grandin, Pornsuk

AU - Song, Hongshuo

AU - Tovanabutra, Sodsai

AU - Shubin, Zhanna

AU - Kim, Dohoon

AU - Paquin-Proulx, Dominic

AU - Eller, Michael A.

AU - Thomas, Rasmi

AU - de Souza, Mark

AU - Wieczorek, Lindsay

AU - Polonis, Victoria R.

AU - Pagliuzza, Amélie

AU - Chomont, Nicolas

AU - Peter, Lauren

AU - Nkolola, Joseph P.

AU - Vingerhoets, Johan

AU - Truyers, Carla

AU - Pau, Maria G.

AU - Schuitemaker, Hanneke

AU - Phanuphak, Nittaya

AU - Michael, Nelson

AU - Robb, Merlin L.

AU - Tomaka, Frank L.

AU - Ananworanich, Jintanat

PY - 2020/4/1

Y1 - 2020/4/1

N2 - We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).

AB - We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).

UR - http://www.scopus.com/inward/record.url?scp=85082109695&partnerID=8YFLogxK

U2 - 10.1038/s41591-020-0774-y

DO - 10.1038/s41591-020-0774-y

M3 - Article

C2 - 32235883

AN - SCOPUS:85082109695

SN - 1078-8956

VL - 26

SP - 498

EP - 501

JO - Nature Medicine

JF - Nature Medicine

IS - 4

ER -

Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption

Abstract

Access to Document

Fingerprint

Cite this